Inclusion Criteria:  Non-small cell lung cancer confirmed by histology. Tumor size is measured according to RECIST standard. Unresectable stage IIIA (N2) and IIIB/IIIC, confirmed by PET-CT/or chest and abdomen CT, brain MRI, and whole body bone scan. 18-75 years old, regardless of gender. The ECOG score is 0-1. Newly treated or underwent neoadjuvant chemotherapy and/or immunotherapy. Have not received chest radiotherapy in the past. Serum hemoglobin ≥10 mg/dL, platelets ≥100000/μL, absolute neutrophil count ≥1500/μL. Serum creatinine ≤1.25 times UNL or creatinine clearance ≥60 ml/min. Serum bilirubin ≤1.5 times UNL, AST (SGOT) and ALT (SGPT) ≤2.5 times UNL, alkaline phosphatase≤ 5 times UNL. FEV1>1 L. CB6 normal range. The patient and his family members agree and sign an informed consent form.  Exclusion Criteria:  Other malignant tumors in the past or during treatment, except for non-melanoma of the skin or carcinoma in situ of the cervix. Any other diseases or conditions are contraindications to chemotherapy (such as active infection, within 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy). Pregnant or breastfeeding women, women who have not undergone a pregnancy test (within 14 days before the first dose), and pregnant women. Those who are pregnant, breastfeeding or have fertility but have not taken contraceptive measures. People with bleeding tendency. Those who participated in other clinical trials within 30 days before participating in this experiment. Drug addiction, long-term alcoholism, and AIDS patients. People with uncontrollable seizures or loss of self-control due to mental illness. People with a history of severe allergies or specific physique. The researcher believes that the patient is inappropriate to participate in this trial.  Exit criteria  The treatment cannot be carried out in accordance with the requirements of the research protocol; The patient has an allergic reaction ≥ grade 4 or a serious adverse reaction to the study drug; The patient is pregnant or has not used adequate contraceptive measures; The researcher judges that the patient should not continue to participate the clinical trial; The subject asked to withdraw.